StereoDive has opened an investment round on Capital Cell to accelerate the development and commercialisation of stereoDiver, its medical software platform for stereotactic neurological procedure planning.

The campaign will support product development, commercial expansion and regulatory milestones, while helping StereoDive bring its technology to more hospitals, clinical teams and strategic partners. Investments start at €1,000.

Supporting safer planning workflows

stereoDiver was created to support safer and more efficient planning in complex neurological procedures, helping neurology and neurosurgery teams work collaboratively through a shared 3D visualisation environment.

Developed from clinical collaboration

The technology was born from a clinical collaboration between Galgo Medical, Hospital del Mar in Barcelona and the Institut Hospital del Mar d’Investigacions Mèdiques — IMIM. It has evolved through close work with clinicians and researchers in epilepsy care and image-guided neurosurgery.

Use of funds

The investment round aims to raise €600,000 to support product development, commercial expansion and regulatory milestones, including CE and FDA-related activities. Investments start at €1,000.

“Epilepsy surgery planning remains highly complex and time-intensive. Our goal is to help clinicians reduce uncertainty, improve safety and give more patients access to effective surgical treatment,”
Antoni Riu
CEO at StereoDive

Read the full press release

For more details about the campaign, the clinical background and StereoDive’s technology, read the full press release below.